By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Solasia Pharma K.K. 

28F, Shinagawa Intercity Tower A
2-15-1, Konan, Minato-ku
Tokyo    108-6028  Japan
Phone: 81-3-6717-4448 Fax: n/a



Company News
Solasia Pharma K.K. And Meiji Seika Pharma Announce License And Distribution Agreement For Episil (Oral Liquid) 12/5/2016 2:43:28 PM
Solasia Pharma K.K. Files New Medical Device Application For episil In Japan And China 5/17/2016 11:28:28 AM
Solasia Pharma K.K. Initiates Phase 2 Study Of Darinaparsin (SP-02) For Peripheral T-Cell Lymphoma 3/28/2016 9:31:12 AM
Solasia Pharma K.K. And Lee's Pharmaceutical Announce License, Promotion And Supply Agreement (The “Agreement”) For Sancuso 11/25/2015 10:45:32 AM
Solasia Pharma K.K. And Meiji Seika Pharma Announce License And Collaboration Agreement For Darinaparsin (Intravenous Formulation) 1/19/2015 10:02:15 AM
Solasia Pharma K.K. Grabs Global Rights To ZIOPHARM Oncology, Inc. (ZIOP.OB)'s Zinapar For Up To $72.2 Million 8/1/2014 8:32:48 AM
Solasia Pharma K.K. Announces New Executive Leadership, Clinical Activities, and China Operations 2/6/2013 9:35:00 AM
Solasia Pharma K.K. to Start China Clinical Trial of Anti-Nausea Patch Product 2/5/2013 1:58:08 PM
Solasia Pharma K.K. Announces Initiation of Darinaparsin Injection (SP-02) Phase 1 Study 10/26/2011 8:13:39 AM
ZIOPHARM, Inc. and Solasia Pharma K.K. Announce License and Collaboration Agreement for Darinaparsin in Asia 3/7/2011 10:32:35 AM